Showing results (511-520 of 661) with videos related to
Sort By:
Pageof 67
Oncotarget|June 11, 2016
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinomaAskar Obulkasim, Bauke Ylstra, Hendrik F van Essen, et al.International Journal of Radiation Oncology, Biology, Physics|November 15, 2016
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell LymphomaLuca Ceriani, Maurizio Martelli, Maria K Gospodarowicz, et al.The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.British Journal of Haematology|November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waitingMaria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy TrialElizabeth C Smyth, Matteo Fassan, David Cunningham, et al.Oncotarget|October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trialMatthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.Pageof 67